Vaxxas Home

Vaxxas Nanopatch™ Technology

Vaccine Application System
Vaxxas Nanopatch Technology
Skip Navigation LinksPages > About Vaxxas > People

About Vaxxas

People

People at Vaxxas

SENIOR TEAM

David Hoey
Chief Executive Officer and Director

Mr. Hoey serves as an advisor to Healthcare Ventures LLC and is based in Boston, USA. He brings more than 20 years of executive-level experience in business development, licensing, strategic planning, and financing for technology companies. His experience spans the preclinical development of small molecule and biologic therapeutics, molecular diagnostic assays and platforms, and analytical instrumentation. Mr. Hoey has completed over $400 million in corporate partnering transactions and equity financings in the United States, Europe, and Japan and has secured extensive contracts for Government sponsored research. Most recently, Mr. Hoey served as vice president of business development at PathoGenetix, a company pioneering single molecule detection technologies for automated identification and strain-typing of microorganisms for biodefense, clinical, and industrial application. During his tenure at PathoGenetix, Mr. Hoey secured more than $55 million from Government contracts and corporate strategic alliances, in addition to a series of equity financings. 

 

Angus Forster
Chief Development and Operations Officer

Angus has worked in medical product development and commercialisation for over 10 years. He previously worked as a consultant for WCI Group and PA Consulting leading both compliance improvement and technical product development programmes. He has worked with a number of device and diagnostic start-up companies to move early stage ideas towards product commercialisation. He also brings considerable experience in coating process development / analysis, medical device design / development, risk management and quality systems. Before working as a consultant Angus spent 5 years with GlaxoSmithKline in pharmaceutical development in the UK.

 

Michael Junger
Head of Medical Device and Process Engineering

Michael has more over 14 years’ experience in medical device manufacturing, research and development.  His previous roles include management of device research and development for assisted reproduction (IVF), which involved developing novel technologies as well as automated manufacturing solutions.  Based on deep experience and skillset covering a diverse micro-manufacturing solutions, Michael has managed teams of formulation scientists, electronic and software engineers, mechanical engineers, and holds several patents in these fields.  With a solid and practical engineering background, Michael brings a pragmatic approach to product design, with strong links to manufacturing and industrial design to ensure ideas generated and tested within the engineering team are quickly and economically transformed into real world products.

 

Charles Ross 
Head of Clinical Operations and Supply

Charles has over 15 years’ experience in the manufacture of sterile pharmaceutical products. He has worked as a project manager at CSL both in Melbourne and Switzerland where he managed the development of a novel aseptic manufacturing process. Following his work at CSL, Charles worked as a GMP consultant specialising in sterile facility design, commissioning and validation before taking on the role as General Manager of a Contract Manufacturing Organisation. Charles brings considerable experience in all facets of facility operations and Good Manufacturing Practice.

 

R&D TEAM

A world class multi-disciplinary research team has been established with individuals from around the world. Members of the technical team have been trained at leading research institutes such as Oxford University, University of California and The University of Queensland with commercial experience in medical device companies. The technical team incorporates specialist knowledge including immunology, engineering, medical product design and chemistry. This fully integrated group works seamlessly across its discipline range to meet the technical challenges associated with Nanopatch™ product development. With access to the latest facilities and equipment, this group is a formidable ally in the product development efforts.

 

DIRECTORS

Dr Paul Kelly
OneVentures Pty Ltd (Vaxxas Pty Ltd Chair)

Paul Kelly is General Partner and Executive Director at OneVentures Pty Ltd, an Australian venture capital firm focused on investing in early stage Australian technology businesses. Dr Kelly has over 15 years of experience in commercialising life science related technologies in Australia, Europe and North America. He has co-founded a number of companies including Gemini Genomics Plc (based in UK and US, acquired by Sequenom in 2001), Agamatrix Inc. and Mears Corporation (both based in the Boston area) and was CEO of Orchid Cellmark (Nasdaq: ORCH) from 2003-2006 and more recently CEO of Medcenter Solutions, an online pharmaceutical marketing company. Dr Kelly has also served on national governmental advisory bodies, including the American Society for Medicine, Law and Ethics and presently is on the Board of Hatchtech Pty Ltd and BioSceptre International Pty Ltd. He is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Honours), and Doctor of Medicine degrees. He is a Fellow of the Australian College of Physicians.

 

Andrew Denver
BSc (Hons), MBA, FAICD

Andrew has served as a director of Universal Biosensors since December 2002 and as Chairman since September 2005. Between 2002 and 2005, Andrew was President of Pall Asia, a subsidiary of Pall Corporation after the acquisition by Pall Corporation of US Filter's Filtration and Separations business, where he was also President. Pall Corporation is a technology based filtration, separation and purification multinational company. Andrew is a director and founder of PFM Cornerstone Ltd and The Principals Funds Management Pty Ltd, companies which help Australian technology businesses, which are predominately in the life sciences industry, commercialize their technologies. Andrew is a non-executive director of SpeeDx Pty Ltd and Cochlear Ltd, all of which are life sciences companies, and until September 2010 and October 2008, was also a non-executive director of CathRx Ltd and Anzon Australia Ltd, respectively. Andrew graduated from the University of Manchester with a Bachelor of Science Degree (Honors) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors.

 

Dr Dean Moss
General Manager, Life Sciences, UniQuest Pty Ltd, BSc, MPhil, PhD, GAICD

Dean Moss has over 25 years' experience in science, academia, business, management and commercialisation in Australia, USA and the UK. He has been managing director or senior business development executive of several health and biotech companies worldwide, including Agen Biomedical, Launch Diagnostics, AMRAD ICT, AMRAD Biotech, and United Drug. He established his own start-up business in the UK, York Medical Technologies.

Prior to moving into the commercial world, Dean was principal R&D scientist at Agen Biomedical. He also worked as an NH&MRC research scientist at the Princess Alexandra Hospital, the Royal Brisbane Hospital and the Queensland Institute of Medical Research. He is a recipient of the Campion-Ma-Playoust Memorial Award for Medical Research.

Dean is a board member of several Australian companies and a member of the investment committee of the pre-seed venture funds Uniseed, the Medical Research Commercialisation Fund and the New Zealand Government's KiwiNet. He has contributed to raising over $50m in venture capital investment.

 

Douglas E. Onsi
Managing Director, HealthCare Ventures, LLC, BA, JD

Doug Onsi has been a partner at HealthCare Ventures since 2007. He was previously at Genzyme Corporation, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology and as Vice President, Business Development. Prior to joining Genzyme, Doug was chief financial officer of Tolerx Inc, a HealthCare Ventures portfolio company. Before joining Tolerx, he was in business development at LeukoSite, also a HealthCare Ventures portfolio company, which was acquired by Millennium Pharmaceuticals. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi is a member of the business and scientific advisory board for FastForward, a subsidiary of the National Multiple Sclerosis Society, and serves on the Cornell University Council. He received a Juris Doctor degree from the University of Michigan Law School and an undergraduate degree in biology from Cornell University.

 

Dr Stephen Thompson
Brandon Capital Partners

Stephen Thompson is a founding partner of Brandon Capital Partners, an Australian life science venture fund manager. Before moving to Australia in 2004 he was a director with Apax Partners based in London and focused on early stage venture investing. Previously he worked with a UK biotechnology company, Cantab Pharmaceuticals, following 10 years of medical research in London and California. Stephen has a BSc, a PhD in immunology and an MBA. He is also a director of Elastagen Pty Ltd, MiReven Pty Ltd and the Cancer Therapeutics CRC.

 

Dr Mark Ashton
Manager of Innovation and Commercial Development, Institute of Molecular Biosciences

Dr Ashton has worked within the biotech and pharmaceutical industry for the past 17 years. He joined UniQuest in 2010 and is currently the Manager of Innovation and Commercial Development for the Institute of Molecular Biosciences. Before joining UniQuest he was the Executive Vice President, Business Development at Evotec AG, a European based Biotech / CRO where he led a team responsible for the global commercial and marketing activities with the world’s leading pharmaceutical and biotechnology companies. Prior to leading the business development group Mark was President, Discovery Services, responsible for the Drug Discovery division of Evotec: a division of approximately 250 chemists and biologists involved in projects ranging from high throughput screening through parallel synthesis and medicinal chemistry to pre-clinical development. He has both operational and commercial experience of a wide range of life science projects and is the author and co-author on a number of reviewed scientific publications and patents.

 

ADVISORY BOARD

Robert Becker
PhD, MBA, Vice President, Corporate Development, MEDInstill

Dr. Becker has been with MEDInstill since 2011, leading the company's business and corporate development efforts. He spent the prior six years at the biotechnology company VaxInnate as the company's Vice President of Business Development. Before his tenure at VaxInnate, he spent 15 years leading vaccine development programs at sanofi pasteur in roles of increasing responsibility, ultimately leaving as a Vice President of Corporate Development. With thirteen years of business development experience, he has expertise in identifying, assessing, negotiating and managing collaborative product development relationships with large pharmaceuticals, biotechnology companies, academic institutions, international zone companies and government agencies. Prior to his business responsibilities, he headed the immunology section and a vaccine development project at sanofi pasteur which addressed the development of vaccines for pneumococcal disease, influenza, JEV, Lyme's disease and pediatric combination vaccines. His academic experience included junior faculty positions at Loyola University Chicago and University of Illinois Chicago in the field of Immunology. Dr. Becker received his PhD from in Microbiology and Immunology from the University of Kansas and his MBA from Columbia University.

 

Julian Hickling
MBA, PhD

Julian has more than 18 years' experience in vaccine research and development in the biotechnology and global health sectors. After completing his PhD in cellular immunology at the University of London, he held postdoctoral positions at the Imperial Cancer Research Fund (London, UK) and ImmuLogic Pharmaceutical Corporation, (Palo Alto, USA).

Moving into UK biotech, Julian worked for more than nine years at Cantab Pharmaceuticals (Cambridge UK), eventually leading the Biologics Research group. At Cantab, he worked on a range of projects including vaccines against herpes viruses, human papillomaviruses and Neisseria meningitidis. Following the acquisition of Cantab by Xenova, Julian joined Cambridge Biostability (Cambridge, UK) as Director of Product Development, managing the research and development of heat-stable vaccine formulations.

Since 2005, Julian Hickling has been a founding director of Working in Tandem Ltd, providing consultancy services in the areas of vaccine R&D, vaccine-delivery devices, public health and immunology. Clients include international public-health organizations such as PATH and WHO, the UK Department of Health and biotechnology, venture capital and technology transfer companies.

 

Professor Ian Frazer
FAA, FRS, CEO and Director of Research, Translational Research Institute Pty Ltd

Professor Ian Frazer is the Chief Executive Officer (CEO) and Research Director of the Translational Research Institute (TRI) in Brisbane, Australia. In his role as CEO, Professor Frazer is charged with leading the $354 million TRI to achieve its mission of being Australia's first institute, and one of only a few in the world, to research, trial and manufacture breakthrough drugs in the one location, once construction is complete in 2012. The TRI will accommodate up to 650 researchers from the four TRI partners: The University of Queensland, Queensland University of Technology, Mater Medical Research Institute and the Princess Alexandra Hospital.

Internationally renowned for the co-creation of the technology for the cervical cancer vaccines, Professor Frazer began his career as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, Professor Frazer accepted a teaching post with The University of Queensland and was appointed Director of The University of Queensland Diamantina Institute in 1991. In early 2011, Professor Frazer relinquished directorship of the Institute to commence in-post as CEO of the TRI. He retains an active research program at the Institute in immune responses to cancer and cancer immunotherapy.

Professor Frazer was awarded the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister's Prize for Science, the 2008 Balzan Prize for Preventive Medicine, the 2009 Honda Prize and was recently elected as a Fellow of the esteemed Royal Society of London.